GlobeImmune, Inc. (GBIM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2015 | 2014 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -7.12 Million | -10.05 Million |
| Net Income | - | - | - | - | -2.76 Million | -16.26 Million |
| Depreciation & Amortization | - | - | - | - | 187.33 Thousand | 295.16 Thousand |
| Deferred income taxes | - | - | - | - | - | 4.59 Million |
| Stock-based compensation | - | - | - | - | 151.81 Thousand | 48.87 Thousand |
| Change in working capital | - | - | - | - | -4.54 Million | -4.52 Million |
| Other non-cash items | - | - | - | - | -159.24 Thousand | 5.79 Million |
| Investing Cash Flow | - | - | - | - | 217.96 Thousand | -166.84 Thousand |
| Investments in PPE | - | - | - | - | -35.74 Thousand | -294.2 Thousand |
| Acquisitions | - | - | - | - | 253.7 Thousand | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | 253.7 Thousand | 127.35 Thousand |
| Financing Cash Flow | - | - | - | - | - | 21.1 Million |
| Debt repayment | - | - | - | - | - | -7.5 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | 17.25 Million |
| Other Financing Activities | - | - | - | - | - | 3.85 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | -338.51 Thousand | -1.16 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | -4.2 Million | -3.36 Million |
| Cash at beginning of period | - | - | - | - | 16.81 Million | 5.92 Million |
| Cash at end of period | - | - | - | - | 9.9 Million | 16.81 Million |
| Capital Expenditure | - | - | - | - | -35.74 Thousand | -294.2 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | - | - | -6.91 Million | 10.88 Million |
| Free Cash Flow | - | - | - | - | -7.16 Million | -10.34 Million |
| Breakdown | 2022 FY | 2021 FY | 2020 FY | 2019 FY | 2016 Q1 | 2015 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | - | - | - | -862.2 Thousand | -2.76 Million |
| Depreciation & Amortization | - | - | - | - | 19.08 Thousand | 187.33 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | 23.97 Thousand | 151.81 Thousand |
| Change in working capital | - | - | - | - | -387.85 Thousand | -4.54 Million |
| Other non-cash items | - | - | - | - | -647.53 Thousand | -159.24 Thousand |
| Investing Cash Flow | - | - | - | - | - | 217.96 Thousand |
| Investments in PPE | - | - | - | - | - | -35.74 Thousand |
| Acquisitions | - | - | - | - | - | 253.7 Thousand |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | 253.7 Thousand |
| Financing Cash Flow | - | - | - | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | 173.6 Thousand | -338.51 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | -561.45 Thousand | -4.2 Million |
| Cash at beginning of period | - | - | - | - | 9.9 Million | 16.81 Million |
| Cash at end of period | - | - | - | - | 8.69 Million | 9.9 Million |
| Capital Expenditure | - | - | - | - | - | -35.74 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | - | - | -1.2 Million | -6.91 Million |
| Free Cash Flow | - | - | - | - | -1.2 Million | -7.16 Million |
NDBKY
UNICHEMLAB
KUKE
600803
NIRAJ
TEVA